image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 2.82
2.17 %
$ 140 M
Market Cap
-2.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AKYA stock under the worst case scenario is HIDDEN Compared to the current market price of 2.82 USD, Akoya Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AKYA stock under the base case scenario is HIDDEN Compared to the current market price of 2.82 USD, Akoya Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AKYA stock under the best case scenario is HIDDEN Compared to the current market price of 2.82 USD, Akoya Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
96.6 M REVENUE
29.09%
-57.7 M OPERATING INCOME
12.90%
-63.3 M NET INCOME
10.36%
-50.9 M OPERATING CASH FLOW
4.85%
3.35 M INVESTING CASH FLOW
123.77%
56.8 M FINANCING CASH FLOW
97.88%
18.8 M REVENUE
-18.78%
-8.35 M OPERATING INCOME
24.68%
-10.5 M NET INCOME
19.90%
-9.26 M OPERATING CASH FLOW
16.17%
13 M INVESTING CASH FLOW
43.79%
-150 K FINANCING CASH FLOW
92.94%
Balance Sheet Akoya Biosciences, Inc.
image
Current Assets 122 M
Cash & Short-Term Investments 83.1 M
Receivables 17 M
Other Current Assets 21.7 M
Non-Current Assets 58.6 M
Long-Term Investments 0
PP&E 20.7 M
Other Non-Current Assets 37.9 M
Current Liabilities 35.3 M
Accounts Payable 11.8 M
Short-Term Debt 3.45 M
Other Current Liabilities 20.1 M
Non-Current Liabilities 91.3 M
Long-Term Debt 82.3 M
Other Non-Current Liabilities 9 M
EFFICIENCY
Earnings Waterfall Akoya Biosciences, Inc.
image
Revenue 96.6 M
Cost Of Revenue 40.3 M
Gross Profit 56.3 M
Operating Expenses 114 M
Operating Income -57.7 M
Other Expenses 5.66 M
Net Income -63.3 M
RATIOS
58.27% GROSS MARGIN
58.27%
-59.68% OPERATING MARGIN
-59.68%
-65.53% NET MARGIN
-65.53%
-117.77% ROE
-117.77%
-35.11% ROA
-35.11%
-44.72% ROIC
-44.72%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Akoya Biosciences, Inc.
image
Net Income -63.3 M
Depreciation & Amortization 8.89 M
Capital Expenditures -3.65 M
Stock-Based Compensation 10.4 M
Change in Working Capital -14.5 M
Others 5.6 M
Free Cash Flow -54.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Akoya Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for AKYA of $5.08 , with forecasts ranging from a low of $3 to a high of $7.5 .
AKYA Lowest Price Target Wall Street Target
3 USD 6.38%
AKYA Average Price Target Wall Street Target
5.08 USD 80.26%
AKYA Highest Price Target Wall Street Target
7.5 USD 165.96%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Akoya Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
30.7 K USD 1
9-12 MONTHS
111 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7 months ago
Jun 11, 2024
Sell 15.6 K USD
McKelligon Brian
President and CEO
- 7500
2.084 USD
7 months ago
Jun 06, 2024
Sell 15.1 K USD
McKelligon Brian
President and CEO
- 7500
2.0085 USD
10 months ago
Mar 20, 2024
Sell 37.2 K USD
McKelligon Brian
President and CEO
- 7500
4.9657 USD
10 months ago
Mar 13, 2024
Sell 37 K USD
McKelligon Brian
President and CEO
- 7500
4.939 USD
10 months ago
Mar 13, 2024
Sell 37 K USD
McKelligon Brian
President and CEO
- 7500
4.938 USD
1 year ago
Dec 19, 2023
Sell 33.6 K USD
McKelligon Brian
President and CEO
- 7500
4.4754 USD
1 year ago
Dec 12, 2023
Sell 31.9 K USD
McKelligon Brian
President and CEO
- 7500
4.2495 USD
1 year ago
Nov 20, 2023
Sell 32.9 K USD
McKelligon Brian
President and CEO
- 7500
4.3868 USD
1 year ago
Sep 07, 2023
Bought 32.2 K USD
Pla Frederic
Chief Operating Officer
+ 7000
4.6 USD
1 year ago
Sep 07, 2023
Bought 59.8 K USD
Pla Frederic
Chief Operating Officer
+ 13000
4.6011 USD
1 year ago
Jun 12, 2023
Bought 100 K USD
Ek John Frederick
CFO
+ 20000
5 USD
1 year ago
Jun 12, 2023
Bought 100 K USD
LAI GOLDMAN MYLA
Director
+ 20000
5 USD
1 year ago
Jun 12, 2023
Bought 100 K USD
Mendel Scott
Director
+ 20000
5 USD
1 year ago
Jun 12, 2023
Bought 1.02 M USD
Winkler Matthew
Director
+ 203388
5 USD
1 year ago
Jun 12, 2023
Bought 600 K USD
SHEPLER ROBERT G
Director
+ 120000
5 USD
1 year ago
Jun 12, 2023
Bought 9.02 M USD
Raffin Thomas A.
Director
+ 1803373
5 USD
1 year ago
Jun 12, 2023
Bought 983 K USD
Raffin Thomas A.
Director
+ 196627
5 USD
1 year ago
Jun 12, 2023
Bought 100 K USD
Raffin Thomas A.
Director
+ 20000
5 USD
1 year ago
Jun 06, 2023
Sell 28.5 K USD
McKelligon Brian
President/CEO
- 5000
5.7074 USD
2 years ago
Dec 13, 2022
Sell 1.32 K USD
Nolan Garry Ph.D.
Director
- 100
13.25 USD
1 year ago
Mar 14, 2023
Sell 43.6 K USD
McKelligon Brian
President/CEO
- 4774
9.135 USD
1 year ago
Mar 14, 2023
Sell 2.24 K USD
McKelligon Brian
President/CEO
- 226
9.918 USD
2 years ago
Dec 13, 2022
Sell 926 K USD
SCHNETTLER THOMAS P
Director
- 71050
13.03 USD
2 years ago
Dec 14, 2022
Sell 182 K USD
DRISCOLL JOSEPH
Chief Financial Officer
- 14574
12.455 USD
3 years ago
Dec 13, 2021
Sell 1.32 K USD
Nolan Garry Ph.D.
Director
- 100
13.25 USD
2 years ago
Dec 06, 2022
Sell 60.4 K USD
McKelligon Brian
President/CEO
- 5000
12.083 USD
2 years ago
Dec 02, 2022
Sell 14.6 K USD
Nolan Garry Ph.D.
Director
- 1100
13.25 USD
2 years ago
Dec 01, 2022
Sell 66.8 K USD
Nolan Garry Ph.D.
Director
- 5000
13.3576 USD
2 years ago
Nov 16, 2022
Sell 3.98 K USD
Nolan Garry Ph.D.
Director
- 300
13.2533 USD
2 years ago
Nov 10, 2022
Sell 50.7 K USD
Nolan Garry Ph.D.
Director
- 3810
13.3085 USD
2 years ago
Nov 11, 2022
Sell 266 K USD
Nolan Garry Ph.D.
Director
- 20000
13.2929 USD
2 years ago
Nov 14, 2022
Sell 7.97 K USD
Nolan Garry Ph.D.
Director
- 600
13.2767 USD
2 years ago
Sep 14, 2022
Sell 110 K USD
Nolan Garry Ph.D.
Director
- 8305
13.2552 USD
2 years ago
Sep 09, 2022
Sell 295 K USD
Nolan Garry Ph.D.
Director
- 22191
13.3089 USD
2 years ago
Sep 12, 2022
Sell 23.9 K USD
Nolan Garry Ph.D.
Director
- 1800
13.3023 USD
2 years ago
Sep 07, 2022
Sell 64.2 K USD
McKelligon Brian
President/CEO
- 5000
12.834 USD
2 years ago
Jun 15, 2022
Sell 51.3 K USD
McKelligon Brian
President/CEO
- 5000
10.252 USD
3 years ago
Dec 09, 2021
Sell 317 K USD
Nolan Garry Ph.D.
Director
- 25000
12.6705 USD
3 years ago
Nov 22, 2021
Bought 328 K USD
Ramachandran Niro Ph.D
Chief Business Officer
+ 25000
13.1317 USD
3 years ago
Nov 19, 2021
Bought 938 USD
Ramachandran Niro Ph.D
Chief Business Officer
+ 73
12.85 USD
3 years ago
Nov 19, 2021
Bought 112 K USD
Mendel Scott
Director
+ 8500
13.16 USD
3 years ago
Nov 18, 2021
Bought 258 K USD
SHEPLER ROBERT G
Director
+ 20000
12.925 USD
3 years ago
Nov 18, 2021
Bought 183 K USD
SHEPLER ROBERT G
Director
+ 15000
12.167 USD
7. News
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease globenewswire.com - 1 month ago
Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants William Bonello - Craig-Hallum Mason Carrico - Stephens Kyle Mikson - Canaccord David Westenberg - Piper Tejas Savant - Morgan Stanley Subbu Nambi - Guggenheim Securities Mark Massaro - BTIG Operator Hello and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 2 months ago
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago. zacks.com - 2 months ago
Akoya Biosciences Reports Third Quarter 2024 Financial Results MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. globenewswire.com - 2 months ago
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. globenewswire.com - 2 months ago
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust globenewswire.com - 3 months ago
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience. globenewswire.com - 3 months ago
Akoya Biosciences, Inc. (AKYA) Q2 2024 Earnings Call Transcript Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Corporate Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley David Westenberg - Piper Sandler Rachel Vatnsdal - JPMorgan Ricki Levitus - Guggenheim Vivian Bais - BTIG Tim Cheung - Capital One Mason Carrico - Stephens Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Second Quarter 2024 Earnings Conference Call. seekingalpha.com - 5 months ago
Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates Akoya Biosciences (AKYA) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.51 per share a year ago. zacks.com - 5 months ago
Akoya Biosciences Reports Second Quarter 2024 Financial Results MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024. globenewswire.com - 5 months ago
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. globenewswire.com - 6 months ago
Lab Instrument Industry Update - New Commercial Entrants Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses. seekingalpha.com - 7 months ago
8. Profile Summary

Akoya Biosciences, Inc. AKYA

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 140 M
Dividend Yield 0.00%
Description Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Contact 100 Campus Drive, Marlborough, MA, 01752 https://www.akoyabio.com
IPO Date April 16, 2021
Employees 330
Officers Mr. Priyam Shah Senior Director of Business Development & Investor Relations Strategy Ms. Jennifer Kamocsay General Counsel Dr. Pascal Bamford Ph.D. Senior Vice President, Research & Development and Laboratory Operations Dr. Niro Ramachandran Ph.D. Chief Business Officer Mr. Brian McKelligon President, Chief Executive Officer & Director Mr. Rob C. Hart CFA, J.D. Secretary